Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sima Rafati

Showing results (61-70 of 136) with videos related to

Pageof 14
Sort By:
Experimental Parasitology|April 27, 2010
Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivityTahereh Taheri, Ali-Hatef Salmanian, Elham Gholami, et al.
Microbial Pathogenesis|January 23, 2026
Exploring miRNAs in Leishmania infection: from immune modulation to theranostic potentialHamzeh Sarvnaz, Shima Hadifar, Taha Masoudsinaki, et al.
Iranian Biomedical Journal|January 19, 2020
Visualization of Leishmania tropica Infection in BALB/c Mice by Bioluminescence ImagingMahdieh Eskandar, Elham Gholami, Negar Seyed, et al.
Vaccine|May 4, 2004
Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasisAzita Zadeh-Vakili, Tahere Taheri, Yasaman Taslimi, et al.
Vaccine|March 31, 2007
Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patientsSima Rafati, Elham Gholami, Nafiseh Hassani, et al.
Plos Neglected Tropical Diseases|July 17, 2019
Correction: Anti-leishmanial activity of Brevinin 2R and its Lauric acid conjugate type against L. major: In vitro mechanism of actions and in vivo treatment potentialsFarnaz Zahedifard, Hyeryon Lee, Joo Hwan No, et al.
Journal of Biotechnology|March 7, 2006
Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergyNariman Aghaei Bandbon Balenga, Farnaz Zahedifard, Richard Weiss, et al.
Molecular and Biochemical Parasitology|August 4, 2004
Type I signal peptidase from Leishmania is a target of the immune response in human cutaneous and visceral leishmaniasisSima Rafati, Ali-Hatef Salmanian, Tahere Taheri, et al.
Vaccines|October 27, 2022
Antibiotic-Free Nanoplasmids as Promising Alternatives for Conventional DNA VectorsNegar Seyed, Farnaz Zahedifard, Sima Habibzadeh, et al.
Iranian Journal of Parasitology|October 21, 2020
Comparison of Protective Potency of DNA and Live Vaccines Expressing A2-CPA-CPB<sup>-CTE</sup> Antigens against Visceral Leishmaniasis in Syrian Hamster as Preliminary StudyYasaman Taslimi, Farnaz Zahedifard, Tahereh Taheri, et al.
Pageof 14

Showing results (61-70 of 136) with videos related to

Sort By:
Pageof 14
Experimental Parasitology|April 27, 2010
Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivityTahereh Taheri, Ali-Hatef Salmanian, Elham Gholami, et al.
Microbial Pathogenesis|January 23, 2026
Exploring miRNAs in Leishmania infection: from immune modulation to theranostic potentialHamzeh Sarvnaz, Shima Hadifar, Taha Masoudsinaki, et al.
Iranian Biomedical Journal|January 19, 2020
Visualization of Leishmania tropica Infection in BALB/c Mice by Bioluminescence ImagingMahdieh Eskandar, Elham Gholami, Negar Seyed, et al.
Vaccine|May 4, 2004
Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasisAzita Zadeh-Vakili, Tahere Taheri, Yasaman Taslimi, et al.
Vaccine|March 31, 2007
Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patientsSima Rafati, Elham Gholami, Nafiseh Hassani, et al.
Plos Neglected Tropical Diseases|July 17, 2019
Correction: Anti-leishmanial activity of Brevinin 2R and its Lauric acid conjugate type against L. major: In vitro mechanism of actions and in vivo treatment potentialsFarnaz Zahedifard, Hyeryon Lee, Joo Hwan No, et al.
Journal of Biotechnology|March 7, 2006
Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergyNariman Aghaei Bandbon Balenga, Farnaz Zahedifard, Richard Weiss, et al.
Molecular and Biochemical Parasitology|August 4, 2004
Type I signal peptidase from Leishmania is a target of the immune response in human cutaneous and visceral leishmaniasisSima Rafati, Ali-Hatef Salmanian, Tahere Taheri, et al.
Vaccines|October 27, 2022
Antibiotic-Free Nanoplasmids as Promising Alternatives for Conventional DNA VectorsNegar Seyed, Farnaz Zahedifard, Sima Habibzadeh, et al.
Iranian Journal of Parasitology|October 21, 2020
Comparison of Protective Potency of DNA and Live Vaccines Expressing A2-CPA-CPB<sup>-CTE</sup> Antigens against Visceral Leishmaniasis in Syrian Hamster as Preliminary StudyYasaman Taslimi, Farnaz Zahedifard, Tahereh Taheri, et al.
Pageof 14